Keywords: UCB, Cimzia, Rhematoid arthritis, Epratuzumab, Lupus

Belgium’s UCB updates on Cimzia and epratuzumab trials

Article | 11 November 2010

Print This

Belgian drugmaker UCB (UCB.BR) has published new data from its Phase IIIb REALISTIC study demonstrating that addition of Cimzia ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in